心房細動治療薬の世界市場2015-2019

◆英語タイトル:Global Atrial Fibrillation Market 2015-2019
◆商品コード:IRTNTR5053
◆発行会社(調査会社):Technavio
◆発行日:2015年1月28日
◆ページ数:67
◆レポート言語:英語
◆レポート形式:pdf
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、心房細動治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、心房細動治療薬の世界市場規模及び予測、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Atrial Fibrillation
According to the NHLBI of the NIH in the US, atrial fibrillation is one of the commonest type of arrhythmia. Atrial fibrillation is similar to another type of arrhythmia of the heart, superventricular tachycardia. The chief difference between these two types of arrhythmia is the consistency of the beats. In superventricular tachycardia, the heart beats are regular and at a very fast pace. Patients with atrial fibrillation experience fast and irregular heartbeats. In patients with atrial fibrillation, electrical signals travel rapidly in an uncontrolled way, which causes convulsion, palpitation or contraction in the atria of the heart. Blood is accumulated inside the atrial chambers, instead of flowing to the ventricular chambers. In this case, blood is not pumped into the ventricles fully. Also, the quantity of blood pumped out of the ventricles to the body is irregular and centered on the arbitrary atrial strokes. This can lead to the formation of blood clot in the atria. Stroke occurs in case the clot moves to the brain, which can cause death of an individual. In atrial fibrillation, the ventricles might beat for 100 to 175 times per minute, which is a stark contrast to the normal heart rate of 60 to 100 beats per minute. Atrial fibrillation is more common in older people and is detected using an ECG reading to find out the abnormalities of the electric signal. Some of the symptoms of atrial fibrillation are rapid and irregular heartbeat, palpitations, dizziness, sweating, chest pain, breathlessness, fatigue, and sometimes loss of consciousness.

TechNavio’s analysts forecast the Global Atrial Fibrillation market to grow at a CAGR of 11.05 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Global Atrial Fibrillation market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs such as anti-arrythmics and anticoagulants used in the treatment of atrial fibrillation.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Atrial Fibrillation market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio’s report, Global Atrial Fibrillation Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Atrial Fibrillation market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Boehringer Ingelheim
• Janssen Pharmaceuticals
• Sanofi

[Other Prominent Vendors]
• ARCA Biopharma
• Armetheon
• Baxter
• Bristol-Myers Squibb
• ChanRx
• Daiichi Sankyo
• Gilead Sciences
• HUYA Biosciences
• Menarini
• Pfizer
• Pierre Fabre
• Servier
• Xention

[Market Driver]
• Growing Patient Base
• For a full, detailed list, view our report

[Market Challenge]
• High Cost of Therapy
• For a full, detailed list, view our report

[Market Trend]
• Shifting Focus on Emerging Markets
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【レポートの目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Product Profiles
04.1.1 Pradaxa/ Prazaxa
04.1.2 Xarelto
04.1.3 Multaq

05.Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology

06.Introduction

07.Disease Overview
07.1 Understanding the Disease
07.2 Classification
07.3 Pathophysiology
07.4 Causes
07.5 Epidemiology
07.6 Management
07.7 Economic Burden

08.Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis

09.Market Segmentation by Class of Drugs
09.1.1 Anticoagulants
09.1.2 Anti-arrythmics

10.Geographical Segmentation

11.Buying Criteria

12.Market Growth Drivers

13.Drivers and their Impact

14.Market Challenges

15.Impact of Drivers and Challenges

16.Market Trends

17.Trends and their Impact

18.Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 Boehringer Ingelheim
18.2.2 Sanofi
18.2.3 Janssen Pharmaceuticals
18.3 Other Prominent Vendors

19.Key Vendor Analysis
19.1 Boehringer Ingelheim
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Segmentation by Revenue 2013
19.1.4 Business Segmentation by Revenue 2012 and 2013
19.1.5 Geographical Segmentation by Revenue 2013
19.1.6 Business Strategy
19.1.7 Recent Developments
19.1.8 SWOT Analysis
19.2 Janssen Pharmaceuticals
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Recent Developments
19.2.4 SWOT Analysis
19.3 Sanofi
19.3.1 Key Facts
19.3.2 Business Description
19.3.3 Business Segmentation
19.3.4 Revenue by Business Segmentation
19.3.5 Revenue Comparison 2012 and 2013
19.3.6 Sales by Geography
19.3.7 Business Strategy
19.3.8 Key Developments
19.3.9 SWOT Analysis

20.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Types of Atrial Fibrillation
Exhibit 3: Risk Factors Associated with Atrial Fibrillation
Exhibit 4: Management of Atrial Fibrillation
Exhibit 5: Economic Burden of Atrial Fibrillation
Exhibit 6: Global Atrial Fibrillation Market 2014-2019 (US$ million)
Exhibit 7: Challenges and Drivers of Global Atrial Fibrillation Market
Exhibit 8: Global Atrial Fibrillation Market Segmentation by Class of Drugs
Exhibit 9: Sub-classification of Anti-arrythmics
Exhibit 10: Segmentation of Global Atrial Fibrillation Market by Geography 2014
Exhibit 11: Buying Criteria of the Global Atrial Fibrillation market
Exhibit 12: World’s Population Aged 60 and Above (2010-2020)
Exhibit 13: The Global Prevalence of Atrial Fibrillation 2006-2016 (Million)
Exhibit 14: Drivers and their Impact on the Key Customer Category of the Global Atrial Fibrillation market
Exhibit 15: Drivers and their Impact on Geographies in Global Atrial Fibrillation Market
Exhibit 16: Global Atrial Fibrillation Market Share Analysis 2014
Exhibit 17: Boehringer Ingelheim: Business Segmentation by Revenue 2013
Exhibit 18: Boehringer Ingelheim: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 19: Boehringer Ingelheim: Geographical Segmentation by Revenue 2013
Exhibit 20: Sanofi SA: Business Segmentation
Exhibit 21: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 22: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 23: Sanofi SA: Sales Revenue by Geographical Segmentation 2013



【掲載企業】

Boehringer Ingelheim, Janssen Pharmaceuticals, Sanofi, ARCA Biopharma , Armetheon, Baxter, Bristol-Myers Squibb, ChanRx , Daiichi Sankyo, Gilead Sciences, HUYA Biosciences, Menarini, Pfizer, Pierre Fabre, Servier, Xention

【レポートのキーワード】

心房細動治療薬、不整脈、製薬、Pradaxa/ Prazaxa、Xarelto、Multaq

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[心房細動治療薬の世界市場2015-2019] (コード:IRTNTR5053)販売に関する免責事項を必ずご確認ください。
★調査レポート[心房細動治療薬の世界市場2015-2019]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆